MEHMO Natural History and Biomarkers
Recruiting · NCT06019182 · Observational (researchers observe without assigning treatment) · Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
View the official record on ClinicalTrials.gov →What this trial is about
This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism/Hypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills. No current treatment for these conditions is available. A major impediment to the testing of potential therapeutic interventions is the lack of well-defined outcome measures. This protocol seeks to identify biochemical and clinical markers to monitor disease progression, and better understand the natural history of these conditions. Any person diagnosed with MEHMO syndrome or related conditions, who can travel to the NIH Clinical Center can participate in this study. The study involves: * General health assessment and evaluation * Imaging studies * Laboratory tests * Collection of blood, urine, spinal fluid, skin biopsy.
Who can take part
Inclusion criteria
- To be eligible to participate in this study, an individual must meet the following criteria:
- Be \>= 1-week of age if affected, or \>=1-month of age if unaffected.
- For Screening:
- Have a combination of signs/symptoms suggestive of MEHMO syndrome,
- AND
- no or inconclusive molecular testing.
- Be a relative of an individual with MEHMO syndrome/eIF2-related condition and whose genetic may be informative for research.
- For Main Study:
- Have a combination of signs/symptoms suggestive of MEHMO syndrome,
- AND
- disease-associated variant(s) or variant(s) of uncertain significance in one of the eIF2-pathway related genes
- Be a relative of an individual with MEHMO syndrome/eIF2-related condition, AND a carrier of the pathogenic or likely pathogenic variant.
- Be a non-affected, non-carrier family member of an individual with MEHMO syndrome or an eIF2-pathway related condition.
Exclusion criteria
- Any individual who, in the opinion of the Investigators, is unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation will be excluded from participation in this study.
Where it is running
1 location listed across 1 US state.
- National Institutes of Health Clinical Center - Bethesda, Maryland, United States